Skip to main content

Patricia Pozo Rosich

.

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

.

.

Projects

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Edoardo Caronna
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00406
Duration: 01/01/2022 - 30/06/2025

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2025

Biomarcadores neurofisiológicos en migraña

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2020/MARTI
Duration: 01/04/2021 - 30/03/2024

Cefaleas y síndromes post-traumatismo craneoencefálico

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM20/00217
Duration: 01/01/2021 - 31/12/2022

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Selen Ozkan

Selen Ozkan

Predoctoral researcher
Clinical and Translational Bioinformatics
Read more
Maria Victoria Gonzalez Martinez

Maria Victoria Gonzalez Martinez

Senior researcher
Pediatric Neurology
Read more
Tamara Garcia Antolinez

Tamara Garcia Antolinez

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.